Nuvation Bio Inc. Class A Common Stock vs Banco Santander SA — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.01 (market cap $1.74B), while Banco Santander SA trades at $13.46 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 110.8× Nuvation Bio Inc. Class A Common Stock's market cap, and Banco Santander SA pays a 2.06% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 1 Days and Banco Santander SA for 55 Days on average.
| NUVB | SAN | |
|---|---|---|
Market Cap | $1.74B | $192.86B |
Volume | 9,289,619 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $9.54 | $15.05 |
52-Week Low | $3.41 | $9.65 |
Typical Hold Time | 1 Days | 55 Days |
Enterprise Value | $1.33B | $360.86B |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →